Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses

Blood Pressure Monitoring

Volumn 6, Issue 1, 2001, Pages 47-57

  Hernández Hernández, Rafael ^a,e   Armas Hernández, Maŕa José ^a   Colina Chourio, José Antonio ^b   Armas Padilla, Maŕa Cristina ^a   López, Luis ^c   Álvarez, Miguel ^d   Pacheco, Beatriz ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

^c Policlínica Santiago de León ^*  (Venezuela)

^d Cardiovascular Center Dr Mariano Alvarez   (Venezuela)

^e Unidad de Terapia Medica   (Venezuela)

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Compliance; Nifedipine GITS

Indexed keywords

AMLODIPINE; NIFEDIPINE;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DIGESTIVE SYSTEM; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE; OFFICE VISITS; THERAPEUTIC EQUIVALENCY; TIME FACTORS; TREATMENT REFUSAL;

EID: 0035062557     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126097-200102000-00008     Document Type: Article

References (35)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
2. Blood pressure control in the hypertensive population
3. WHO - ISH Hypertension Guidelines for the Management of Hypertension
4. Management of difficult to control hypertension
5. Is there a difference in hypertensive patient compliance between a once a day or twice a day nifedipine?
6. Use of drugs with more than a twenty four hour duration of action
7. The patient's view of hypertension and compliance
8. Erratic patient compliance with prescribed drug regimens: Target for drug delivery systems
9. Partial compliance: Implication for clinical practice
10. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: Comparison of once daily versus twice daily regimen
11. Underutilization of antihypertensive drugs and associated hospitalization
12. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers
13. Persistence of antihypertensive effect after "missed doses" of calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination half-life
14. Nifedipine: Individual responses and concentration-effect relationships
15. Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists
16. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem
17. The nifedipine gastrointestinal and therapeutic system (GITS): Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties
18. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring
19. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily
20. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition
21. A double blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients
22. Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: Results of the MATH trial
23. Efficacy and safety of enalapril versus extended-release nifedipine for the treatment of hypertension. Results of a multicenter trial
24. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension
25. Efficacy and tolerability of felodipine and amlodipine in the treatment of mild to moderate hypertension. A randomized double blind multicentre trial
26. The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure
27. Effect of amlodipine on 24hour ambulatory blood pressure in hypertensive patients
28. Trough: Peak ratio of the blood pressure response to dihydropyridine calcium antagonists
29. 24-Hour blood pressure profiles in patients with hypertension treated with amlodipine or nifedipine GITS
30. Trough: Peak ratio: Clinically useful or practically irrelevant
31. Trough: Peak ratio of the blood pressure response to dihydropyridine calcium antagonists
32. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders
33. Amlodipine lowers blood pressure without increasing sympathetic activity or activating the renin angiotensin system in patients with essential hypertension
34. A comparative assessment of amlodipine and felodipine ER: Pharmacokinetic and pharmacodynamic indices
35. Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients